Infinity Pharmaceuticals Inc. stunned investors early Tuesday by disclosing disappointing results from the registration-focused DYNAMO study. The phase II trial, which evaluated the efficacy and safety of duvelisib – the oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma – as a monotherapy in 129 patients with refractory indolent non-Hodgkin lymphoma (iNHL), met its primary endpoint by demonstrating an overall response rate (ORR) of 46 percent.